Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 929 participants.

Also called NCT02738151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 929 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02738151
  • EudraCT 2015-005101-36
Other papers using this trial's data
  • More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial Diabetes care, 2018-10 DOI, PubMed 30104294

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Croatia, Czechia, Denmark, France, Greece, Hungary, Israel, Italy, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02738151. Randomized; no masking; primary purpose treatment. Start 2016-05-19 (registry gives no type); primary completion 2017-08-15 (actual). Results posted on 2018-09-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Acronym
BRIGHT
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin glargine, 300U/mL
Intervention (Drug)
Insulin degludec, 100 U/mL
Intervention (Drug)
Non-insulin anti-diabetic treatment
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02738151
Content hash
c724851a4d77c407acd76152f9c2ef418e530516e41172ea4a9d142572b265ea